Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration
Effectiveness and Safety of Subtenon Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration
Sponsor: Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
This PHASE1/PHASE2 trial investigates Primary Open-Angle Glaucoma and Retinal Degeneration and is currently ongoing. Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation leads this study, which shows 9 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
Status: Enrolling By Invitation → Unknown Status
▶ Show 4 earlier versions
-
Jun 2018 — Aug 2019 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Aug 2017 — Oct 2017 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Enrolling By Invitation PHASE1_PHASE2
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
For direct contact, visit the study record on ClinicalTrials.gov .